CONQUEST Featured in “Endpoints News”
SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of “Endpoints News” to announce that CONQUEST has received FDA OK to proceed and share more about the specifics of this platform clinical trial:
“The study, called CONQUEST, has the support of two Big Pharma partners. Sanofi and Boehringer Ingelheim will test two of their top experimental drugs — amlitelimab and BI 1015550— and cover the trial’s estimated cost of $80 million, Evnin said. All told, he expects the first cycle of the study to enroll 400 scleroderma patients with interstitial lung disease, producing results in 2026.”
Learn more about how the SRF is spurring scleroderma drug research by reading the full story.
